A rare condition known as pulmonary arterial hypertension (PAH) causes the pulmonary microvasculature to gradually disappear, increasing pulmonary vascular resistance and increasing the risk of early mortality. According to the current classification, PAH can be linked to exposure to specific Pulmonary Arterial Hypertension Drug or toxins, especially pharmaceuticals that reduce appetite, like benfluorex, fenfluramine derivatives, and aminorex. Several medications were taken off the market once it was determined that they were PAH risk factors. Serotonin was shown to work as a growth factor for the smooth muscle cells in the pulmonary artery, which is thought to be the mechanism for the increase in serotonin levels. Although they were less widely used, amphetamines, phentermine, and mazindol are also thought to be potential risk factors for Pulmonary Arterial Hypertension.
Dual Src/Abl kinase inhibitor dasatinib, which is used to treat chronic myelogenous leukaemia, has been linked to severe PAH instances that may partially improve following dasatinib removal. Several investigations have questioned whether interferon therapy may cause endothelial dysfunction, and a few cases of Pulmonary Arterial Hypertension Drugs have been linked to the medication. More research is required to determine whether patients are at risk of drug-induced PAH because this condition is still a rare side effect of these medications and may be individualized.
